Hylenex
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Healthy
Conditions
Healthy
Trial Timeline
Nov 1, 2005 → Jan 1, 2006
NCT ID
NCT00311519About Hylenex
Hylenex is a approved stage product being developed by Halozyme Therapeutics for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT00311519. Target conditions include Healthy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00435604 | Phase 1 | Completed |
| NCT00593281 | Phase 3 | Completed |
| NCT00311519 | Approved | Completed |
Competing Products
20 competing products in Healthy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 | AstraZeneca | Phase 1 | 33 |
| Valsartan | Novartis | Phase 1 | 33 |
| CSL112 + Placebo | CSL | Phase 1 | 32 |
| UT-15C | United Therapeutics | Phase 1 | 30 |
| VNA-318 + Placebo | Biotrial | Phase 1 | 25 |
| Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + Placebo | Trevena | Phase 1 | 25 |
| TRV130 + Moxifloxacin + Placebo | Trevena | Phase 1 | 25 |
| Radiolabeled TRV130 | Trevena | Phase 1 | 25 |
| TRV130A + Dextrose in Water | Trevena | Phase 1 | 25 |
| TRV734 | Trevena | Phase 1 | 25 |
| ALT02 + EU-licensed Herceptin + US-licensed Herceptin | Alteogen | Phase 1 | 33 |
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 33 |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 1 | 28 |
| MORF-057 + Placebo for MORF-057 | Eli Lilly | Phase 1 | 33 |
| Propranolol + Pseudoephedrine | Eli Lilly | Pre-clinical | 23 |
| LY2157299 | Eli Lilly | Phase 1 | 33 |
| Lasmiditan + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3015014 + Placebo | Eli Lilly | Phase 1 | 33 |
| LOXO-783 | Eli Lilly | Phase 1 | 33 |
| LY2541546 - IV + LY2541546 - SC + Placebo | Eli Lilly | Phase 1 | 33 |
Other Products from Halozyme Therapeutics
Commercial Hylenex® recombinant (hyaluronidase human injection) + Precommercial Hylenex recombinant (hyaluronidase human injection) + Insulin lispro + Insulin aspart + Insulin glulisineApproved
82
large protein moleculeApproved
82
Sham Injection + Recombinant human hyaluronidase PH20 + Insulin aspart + Insulin lisproApproved
82
Rapid Acting insulin with pre-treatment of rHuPH20Approved
82
HylenexPhase 3
74